Evidence map›Paper›PMID 21994761›Full record

ReviewViruses2011

RIG-I like receptors in antiviral immunity and therapeutic applications.

Reneé C Ireton, Michael Gale

Abstract readReview
In one paragraph

Review in Viruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Exosome mediated multidrug resistance in cancer.American journal of cancer research · 2018
    Review
  19. Intracellular Antiviral Immunity.Advances in virus research · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Reneé C IretonDepartment of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA. rireton@u.washington.edu
Michael Gale

Funding

The Burden of Chikungunya and Dengue Infection in KenyaU54AI081680 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SMITH, RICHARD D · 2009 to 2013
$40.4M
West Nile Virus and host control of innate defensesU19AI083019 · NIAID · UNIVERSITY OF WASHINGTON · PI SUTHAR, MEHUL SHAMAL · 2009 to 2018
$22.5M
PROTEOMICS COREP30DA015625 · NIDA · UNIVERSITY OF WASHINGTON · PI KATZE, MICHAEL G · 2002 to 2012
$18.9M
Mechanisms Of Pathogen Recognition And Innate Immune Control Of Hepatitis C VirusU19AI088778 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2010 to 2014
$4.2M
The Host Response to Hepatitis C VirusR01AI060389 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GALE, MICHAEL · 2003 to 2012
$3.4M
INNATE IMMUNE DEFENSE AGAINST HCV and HIV: THE CHIMERIC MOUSE MODELR01DA024563 · NIDA · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2007 to 2011
$1.7M
Cell-Specific Programs of Host Defense Against West Nile VirusR01AI074973 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2009 to 2010
$774k
NIAID NIH HHS AI2008038NIAID NIH HHS HHSN272200900035CNIAID NIH HHS R01AI060389NIAID NIH HHS R01 AI074973NIAID NIH HHS R01AI074973NIAID NIH HHS U19 AI083019NIAID NIH HHS U19AI083019NIAID NIH HHS U19 AI088778NIAID NIH HHS U19AI088778NIAID NIH HHS U54 AI081680NIAID NIH HHS U54AI081680NIDA NIH HHS P30 DA015625NIDA NIH HHS P30DA015625NIDA NIH HHS R01 DA024563NIDA NIH HHS R01DA024563
6 · The paper itself

Abstract

The RNA helicase family of RIG-I-like receptors (RLRs) is a key component of host defense mechanisms responsible for detecting viruses and triggering innate immune signaling cascades to control viral replication and dissemination. As cytoplasm-based sensors, RLRs recognize foreign RNA in the cell and activate a cascade of antiviral responses including the induction of type I interferons, inflammasome activation, and expression of proinflammatory cytokines and chemokines. This review provides a brief overview of RLR function, ligand interactions, and downstream signaling events with an expanded discussion on the therapeutic potential of targeting RLRs for immune stimulation and treatment of virus infection.

Indexed as

Immunity, InnateAnimalsAntiviral AgentsDEAD-box RNA HelicasesEnzyme ActivatorsHumansVirus DiseasesVirusesVirus Physiological PhenomenaAntiviral AgentsDEAD-box RNA HelicasesEnzyme ActivatorsadjuvantinflammationRIG-I

Identifiers

PMID21994761
PMCPMC3185779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.